[Extrinsic coagulation pathway in peritoneally dialyzed patients treated with erythropoietin].
In chronic renal failure, disturbances in hemostasis are predominantly due to the defective platelet function and platelet/vessel wall interactions. Erythropoietin, used in the treatment of renal anemia, affects hemostasis in dialyzed patients. The work was aimed at assessing the components of extrinsic coagulation pathway in patients on continuous ambulatory peritoneal dialysis (CAPD) in the course of erythropoietin therapy. The studies were performed on 11 CAPD patients, administered with subcutaneous erythropoietin in a dose of 2000 U three times a week for a 3 months time. Hemoglobin, hematocrit and erythrocyte count increased significantly after 1 month of the treatment. Tissue factor, tissue factor pathway inhibitor (total, free and truncated), factor VII and X as well as thrombomodulin-marker of endothelial celi injury did not change significantly during 3 months of erythropoietin therapy when compared to the baseline values. Erythropoietin treatment in CAPD patients did not affect significantly extrinsic coagulation pathway and endothelial function.